The Merck Group, Amgen, Shionogi and Digital Garage-backed digital cognitive treatment developer will get a Nasdaq Capital Market listing through the deal.

US-based digital therapeutics developer Akili Interactive agreed yesterday to a $1bn reverse merger with special purpose acquisition company Social Capital Suvretta Holdings Corp 1, marking exits for pharmaceutical firms Merck Group, Amgen and Shionogi & Co. The deal will benefit from $162m in private investment in public equity (PIPE) financing, consisting of $100m from Social…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.